Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
ESMO 2023
It's been a week since #WCLC26!
Catch up on the latest data and updates in #LungCancer with our exclusive video interviews 📊🫁
🎥: https://ow.ly/w6yp50ZPMcX
#Oncology #NSCLC #SCLC #Mesothelioma #LCSM @IASLC
At #WCLC26, Hui Jing Hoe explores clinical, pathologic, genomic and immunophenotypic characterization of #KRAS G12V #NSCLC 🫁🧬🔍
Watch:
#Oncology #LungCancer #LCSM @IASLC
Clinical, pathologic, genomic and immunophenotypic characterization of KRAS G12V NSCLC
Hui Jing Hoe, MBBS, Dana-Farber Cancer Institute, Boston, MA, shares insights into a study characterizing the clinical...
ow.ly
It was great to speak with Marcelo Bonomi at #ASCO26 to discuss findings from a Phase II trial of metronomic carboplatin and paclitaxel with cemiplimab in R/M #HNSCC 💉
The combination showed meaningful antitumor activity and cytokine profiling indicated immune-mediated
🎙️ Explore #WCLC26 highlights in this week’s VJOncology podcast, covering highly anticipated trials such as PAPILLON and REZILIENT 3, updates in #SCLC and #mesothelioma, and more! Listen now for expert insights from Seoul! ▶️
🔗https://www.vjoncology.com/podcast/lung-cancer-highlights-from-wclc-2026/
🍎 Apple Podcasts:
In a recent interview at #WCLC26, Massimiliano Cani explores results from the RISP trial evaluating cytisine for smoking cessation in older adults 🫁 🚬🚫
Watch:
#Oncology #LungCancer #LCSM @IASLC
This video is available on the Lung Cancer Channel on
RISP: cytisine for smoking cessation in patients over the age of 65
Massimiliano Cani, MD, University of Turin, Turin, Italy, discusses results from the RISP trial (NCT05766046), evaluatin...
ow.ly
ESMO 2023
It's been a week since #WCLC26!
Catch up on the latest data and updates in #LungCancer with our exclusive video interviews 📊🫁
🎥: https://ow.ly/w6yp50ZPMcX
#Oncology #NSCLC #SCLC #Mesothelioma #LCSM @IASLC
At #WCLC26, Hui Jing Hoe explores clinical, pathologic, genomic and immunophenotypic characterization of #KRAS G12V #NSCLC 🫁🧬🔍
Watch:
#Oncology #LungCancer #LCSM @IASLC
Clinical, pathologic, genomic and immunophenotypic characterization of KRAS G12V NSCLC
Hui Jing Hoe, MBBS, Dana-Farber Cancer Institute, Boston, MA, shares insights into a study characterizing the clinical...
ow.ly
It was great to speak with Marcelo Bonomi at #ASCO26 to discuss findings from a Phase II trial of metronomic carboplatin and paclitaxel with cemiplimab in R/M #HNSCC 💉
The combination showed meaningful antitumor activity and cytokine profiling indicated immune-mediated
🎙️ Explore #WCLC26 highlights in this week’s VJOncology podcast, covering highly anticipated trials such as PAPILLON and REZILIENT 3, updates in #SCLC and #mesothelioma, and more! Listen now for expert insights from Seoul! ▶️
🔗https://www.vjoncology.com/podcast/lung-cancer-highlights-from-wclc-2026/
🍎 Apple Podcasts:
In a recent interview at #WCLC26, Massimiliano Cani explores results from the RISP trial evaluating cytisine for smoking cessation in older adults 🫁 🚬🚫
Watch:
#Oncology #LungCancer #LCSM @IASLC
This video is available on the Lung Cancer Channel on
RISP: cytisine for smoking cessation in patients over the age of 65
Massimiliano Cani, MD, University of Turin, Turin, Italy, discusses results from the RISP trial (NCT05766046), evaluatin...
ow.ly
Watch all videos from ESMO 2023!
View all
GU at ESMO 2023!
View allLung cancer at ESMO 2023!
View all
Check out some of the experts who we will be interviewing this year!
